Shilpa Medicare share price
NSE: SHILPAMEDBSE: 530549Pharmaceuticals & BiotechnologySmall Cap
Shilpa Medicare Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1995 on BSE, Dec 2009 on NSE
Last close ₹955.60up ₹20.00 (2.14%)BSE ₹954.65
Share price at the NSE close on 30 Oct 2026. Previous close ₹935.60.
30 Oct: open ₹955.90, high ₹979.80, low ₹930.30
52-week range of traded prices to 30 Oct 2026
₹259.50Low, 27 Jan 2026₹1,095.00High, 1 Oct 2026
- Under NSE's long-term additional surveillance, stage I, on the list for 30 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.
- Next results date: the board meets on 5 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹18,690 Cr637th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 62.86
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 70.04
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 7.21
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.06%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 12.0%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes ₹30 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.8%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 10.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.25
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 9,03,85439.8% delivered
About Shilpa Medicare
Shilpa Medicare Limited is a pharmaceutical company from Raichur, Karnataka, that makes active pharmaceutical ingredients (the active substance in a medicine), finished medicines and biologics (medicines made from living cells), and develops and manufactures drugs under contract (CDMO) for other drug companies.1 Its finished medicines cover oncology, neurology, dermatology, gastroenterology and supportive care, and its API business supplies customers in regulated markets such as the United States, Europe and Japan.23
The API business is run through the wholly owned subsidiary Shilpa Pharma Lifesciences, and finished medicines are made at plants in Jadcherla and Dabaspet.34 Biologics sit in 2 wholly owned subsidiaries: Shilpa Biologicals, with its plant at Dharwad, and Shilpa Biocare, with its plant at Kadechur, Karnataka.56 Its brands include Noduca (NorUDCA) for non-alcoholic fatty liver disease, OERIS, an ondansetron injection against nausea from chemotherapy, and Srbumin, its recombinant human albumin.789
The company started operations in 1987 as an API maker, began commercial production in November 1989, and listed on BSE in 1995 and on NSE in 2009.10 The company law tribunal approved the merger of its wholly owned subsidiary Shilpa Therapeutics into the company by an order of 27 Feb 2026, with 1 Apr 2025 as the date from which the accounts are combined.11 Chairman Omprakash Inani is a non-executive promoter director, and Vishnukant Bhutada is managing director.1213
Shilpa Medicare key points
Results
- In the quarter to Jun 2026, consolidated revenue was ₹469 crore, up 43% from ₹328 crore a year earlier, its highest quarterly revenue.1415
- In the quarter to Jun 2026, consolidated EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹139 crore, up 42%, and consolidated profit after tax ₹101 crore, up 115%, with a negative tax rate from a deferred tax reversal.1617
- In the year to Mar 2026, consolidated gross revenue was ₹1,53,887 lakh against ₹1,28,643 lakh, and consolidated total comprehensive income (profit plus gains and losses booked directly to equity) ₹24,719 lakh against ₹7,599 lakh.18
Business segments
- API. In the year to Mar 2026, API revenue, including supplies to the company's own formulations business, grew 17% on a like to like basis to ₹985 crore; oncology APIs contributed ₹455 crore and non-oncology APIs ₹390 crore.19
- Specialty CDMO (within API). Specialty CDMO, contract work on APIs, peptides and polymers for other drug companies, is counted within the API division; it had revenue of ₹110 crore in the year to Mar 2026 and more than 25 active programmes.2021
- Formulations. Formulations (finished medicines) revenue grew 30% to ₹618 crore in the year to Mar 2026 from ₹474 crore, the segment's highest annual revenue.22
- Biologics. Biologics revenue was ₹149 crore in the year to Mar 2026, about 10% of consolidated revenue, and ₹52 crore in the quarter to Jun 2026, up 42%.2324
Formulations revenue by market
- Formulations revenue by market, ₹ crore25
Item year to Mar 2026 year to Mar 2025 Europe 223 111 Rest of the world 123 99 United States 80 48 India 72 26 Licensing and services 120 –
Plants and capacity
- API Unit I at Raichur has 11 manufacturing blocks with 650 KL (kilolitres) of reactor capacity, and API Unit II at Raichur has 10 blocks with 510 KL.2627
- The Jadcherla formulations plant can make about 25 million tablets, 4 million capsules, 3 million injectables and 2 million freeze-dried vials a year; the Bengaluru plant about 50 million oral films and 30 million transdermal patches.28
- On its earnings call of 5 Aug 2026, the company said its peptide manufacturing block in India is to complete commissioning by the end of the year to Mar 2027.29
- In the quarter to Jun 2026, the company spent about ₹114 crore on capital spending.30
Customers and partners
- Orion Corporation is the exclusive European partner for Shilpa's recombinant human albumin for therapeutic use, and for a nivolumab biosimilar (a near-copy of an off-patent biological medicine) that Shilpa co-develops and supplies.3132
- As of its presentation of 5 Aug 2026, the US FDA had issued a complete response letter (declining approval for now) on Unicycive Therapeutics' Oxylanthanum Carbonate, for high blood phosphate, citing deficiencies at a third-party finished-dose site; Shilpa is its exclusive CDMO partner.3334
Research and development
- Research runs across 5 research centres in India with more than 400 scientists and specialists; by Mar 2026 the company had filed 597 patents and been granted 126.3536
- Shilpa had 290 drug master files (dossiers regulators use to approve an API supplier) by Jun 2026, and more than 860 formulation filings at Mar 2026, with over 50 new approvals in that year.3736
- NorUDCA, launched in India in the quarter to Dec 2025 with 3 marketing partners, made Shilpa the first company in India with regulatory approval for a fatty liver disease (NAFLD) treatment, the company says.382139
- On its earnings call of 5 Aug 2026, the company said it expects to launch the biosimilar Aflibercept in India in the year to Mar 2027, and Abraxane, Enzalutamide and Abiraterone formulations in the year to Mar 2028.40
Recent events
- In an exchange filing of 10 Oct 2026, the company said Unit 4 at Jadcherla had received GMP (good manufacturing practice) certification from AGES, Austria, after an inspection from 27 to 30 July 2026.41
- On 11 Sep 2026, CDSCO's Subject Expert Committee approved granting marketing authorisation for OERIS, designed to act for up to 120 hours from one dose; launch in India awaits final authorisation.4243
- On 7 Jul 2026, India Ratings upgraded the credit rating (an agency's view of how safely a borrower repays) on Shilpa Medicare's bank facilities to IND AA- from IND A+, with a stable outlook.44
Litigation and regulatory matters
- On 23 Jun 2026, Shilpa Biologicals settled a commercial suit by Sartorius Stedim India, which had claimed ₹20,13,47,308 plus interest, by agreeing before a Bengaluru commercial court to pay ₹9,00,00,000.45
- A US FDA pre-approval inspection of Unit VI at Dabaspet ended on 29 May 2026 with a Form 483 (a list of inspectors' observations) of 5 procedural observations, none repeat or related to data integrity; the company said it would respond within the stipulated time.46
Last updated
All 46 sources, each with its page
- 1. Annual report, 13 Aug 2026, page 63
- 2. Annual report, 13 Aug 2026, page 25
- 3. Annual report, 13 Aug 2026, page 21
- 4. Annual report, 13 Aug 2026, page 25
- 5. Annual report, 13 Aug 2026, page 65
- 6. Annual report, 13 Aug 2026, page 58
- 7. Annual report, 13 Aug 2026, page 64
- 8. Annual report, 13 Aug 2026, page 6
- 9. Annual report, 13 Aug 2026, page 36
- 10. Annual report, 13 Aug 2026, page 167
- 11. Annual report, 13 Aug 2026, page 74
- 12. Annual report, 13 Aug 2026, page 89
- 13. Annual report, 13 Aug 2026, page 57
- 14. Investor presentation, 5 Aug 2026, page 8
- 15. Investor presentation, 5 Aug 2026, page 8
- 16. Investor presentation, 5 Aug 2026, page 8
- 17. Earnings call, 5 Aug 2026, page 5
- 18. Annual report, 13 Aug 2026, page 69
- 19. Annual report, 13 Aug 2026, page 21
- 20. Annual report, 13 Aug 2026, page 69
- 21. Investor presentation, 5 Aug 2026, page 15
- 22. Annual report, 13 Aug 2026, page 64
- 23. Annual report, 13 Aug 2026, page 65
- 24. Earnings call, 5 Aug 2026, page 6
- 25. Annual report, 13 Aug 2026, page 64
- 26. Investor presentation, 5 Aug 2026, page 32
- 27. Annual report, 13 Aug 2026, page 24
- 28. Annual report, 13 Aug 2026, page 64
- 29. Earnings call, 5 Aug 2026, page 3
- 30. Earnings call, 5 Aug 2026, page 5
- 31. Investor presentation, 5 Aug 2026, page 23
- 32. Investor presentation, 5 Aug 2026, page 20
- 33. Investor presentation, 5 Aug 2026, page 27
- 34. Investor presentation, 5 Aug 2026, page 29
- 35. Annual report, 13 Aug 2026, page 41
- 36. Annual report, 13 Aug 2026, page 70
- 37. Investor presentation, 5 Aug 2026, page 13
- 38. Investor presentation, 5 Aug 2026, page 29
- 39. Annual report, 13 Aug 2026, page 70
- 40. Earnings call, 5 Aug 2026, page 4
- 41. Exchange filing, 10 Oct 2026, page 1
- 42. Exchange filing, 11 Sep 2026, page 1
- 43. Exchange filing, 11 Sep 2026, page 2
- 44. Exchange filing, 7 Jul 2026, page 2
- 45. Exchange filing, 24 Jun 2026, page 1
- 46. Exchange filing, 30 May 2026, page 1
Results
Consolidated; ₹ crore.Shilpa Medicare quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +27.9%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +167.6%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹466 Crup 6.59%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹101 Crdown 6.41%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 21.7%
Revenue by quarter
Peak revenue ₹466 Cr, quarter to Jun 2026; lowest ₹319 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 344 | 319 | 331 | 321 | 370 | 410 | 437 | 466 |
| Net profit | 18 | 32 | 15 | 47 | 44 | 45 | 108 | 101 |
| Net margin | 5.2% | 10.0% | 4.4% | 14.6% | 11.9% | 10.9% | 24.7% | 21.7% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,539 Crup 19.62%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹243 Crup 210.79%
- Net margin
- 15.8%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 1 of the 8 years with results on record
The years either side of a change of basis do not compare. From the year to Mar 2018, GST replaced excise duty on 1 Jul 2017, and revenue before that day includes the duty.
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 784what Revenue, Mar 2017, includes. This period's revenue includes excise duty of ₹4.65 crore, a tax on the goods the company makes that it collects and pays to the government. | 792what Revenue, Mar 2018, includes. This period's revenue includes excise duty of ₹2.71 crore, a tax on the goods the company makes that it collects and pays to the government. | 733 | 908 | 901 | 1,146 | 1,050 | 1,152 | 1,286 | 1,539 |
| Net profit | 109 | 105 | 110 | – | 148 | – | −32 | 32 | 78 | 243 |
| Net margin | 13.9% | 13.3% | 14.9% | – | 16.4% | – | −3.1% | 2.8% | 6.1% | 15.8% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share. Net profit is left blank for Mar 2020 and Mar 2022: the profit stated for the year is its quarters' profit belonging to the company's shareholders added up, which leaves out the other owners' share those quarters state, so the group's profit is not stated.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticle, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Mar 2018: days before it are of the company before the change.Shilpa Medicare PE ratio and valuation
Price to earnings
At or below today's level on 74% of 1,776 trading days since Jun 2017.
LowestHighest
Its median42.20Industry median27.77
Price to book
At or below today's level on 98% of 964 trading days over the last 5 years.
LowestHighest
Its median2.46Industry median2.89
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 32% of 2,479 trading days over the last 10 years.
LowestHighest
Its median0.13%Industry median0.49%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +5.4% | +209.5% | −66.0% | 0.2% |
| 3 years | +45.1% | +88.1% | −22.9% | 0.1% |
| 5 years | +16.0% | +6.5% | +8.8% | 0.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years includes one-off items (exceptional items and the result of businesses sold or closed) of more than a tenth of the profit of the years to Mar 2021, Mar 2025 and Mar 2026.
Mutual fund holdings
30 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 9 of the 16 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 30 funds holding Shilpa Medicare
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 3
- CutCut. Funds that held fewer shares than at the end of the month before.
- 13
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 13
| Fund | |||
|---|---|---|---|
 Bandhan Small Cap FundBandhan Mutual Fund | 20,49,541 | 0.60% | ₹214.6 Cr |
 ICICI Prudential ELSS - Tax Saver FundICICI Prudential Mutual Fund | 18,14,657 | 1.41% | ₹190.0 Cr |
 HDFC Pharma and Healthcare FundHDFC Mutual Fund | 10,80,751 | 3.23% | ₹113.2 Cr |
 Aditya Birla Sun Life Small Cap FundAditya Birla Sun Life Mutual Fund | 5,54,077 | 0.95% | ₹58.0 Cr |
 TRUSTMF Small Cap FundTrust Mutual Fund | 3,65,016 | 0.99% | ₹38.2 Cr |
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 3,16,154 | 1.37% | ₹33.1 Cr |
| Aditya Birla Sun Life Manufacturing Equity FundAditya Birla Sun Life Mutual Fund | 3,14,865 | 2.38% | ₹33.0 Cr |
 WhiteOak Capital Mid Cap FundWhiteOak Capital Mutual Fund | 2,92,082 | 0.41% | ₹30.6 Cr |
 Union Small Cap FundUnion Mutual Fund | 2,37,777 | 0.91% | ₹24.9 Cr |
| ICICI Prudential Exports & Services FundICICI Prudential Mutual Fund | 2,35,800 | 1.70% | ₹24.7 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 30 Oct 2025.Shilpa Medicare insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Others0 purchases, 1 saleNo purchase₹0.42 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹0.42 Cr
- Promoters and promoter group: no market trade · 6 pledge filings of unclear kind
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Shilpa Medicare competitors and peers
Pharmaceuticals, 215 listed companies, priced on 30 Oct 2026. The table lists the 8 companies closest to Shilpa Medicare in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 WockhardtWOCKPHARMA | 30,891 | 75.53 | 6.25 | +18.4% | – | 8.8% | 7.4% | 0.00% |
 Rubicon ResearchRUBICON | 26,659 | 92.50 | 20.68 | – | – | 22.4% | 25.8% | 0.09% |
 Neuland LaboratoriesNEULANDLAB | 25,275 | 50.78 | 13.48 | +78.3% | +182.6% | 29.3% | 32.1% | 0.17% |
 Granules IndiaGRANULES | 22,907 | 34.58 | – | +24.8% | +38.1% | 15.1% | 15.1% | 0.21% |
 Onesource Specialty PharmaONESOURCE | 17,924 | – | 3.03 | +10.7% | −103.9% | 0.0% | 1.5% | 0.00% |
 Caplin Point LaboratoriesCAPLIPOINT | 17,677 | 26.57 | 4.93 | +15.0% | +17.7% | 20.7% | 19.8% | 0.34% |
 Alivus Life SciencesALIVUS | 17,376 | 25.94 | 4.79 | +8.2% | +26.3% | 20.2% | 23.1% | 0.35% |
 Cohance LifesciencesCOHANCE | 16,999 | 160.02 | 4.35 | +41.2% | −58.5% | 3.8% | 3.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Shilpa Medicare dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹0.60 a share, year to Mar 2026.
| Ex-date | Type | Per share |
|---|---|---|
| 4 Sep 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹0.60 |
| 17 Sep 2025 | Final | ₹1.00 |
| 19 Sep 2022 | Final | ₹1.10 |
| 20 Sep 2021 | Final | ₹1.10 |
| 16 Mar 2020 | Interim | ₹1.10 |
| 12 Sep 2019 | Final | ₹1.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Shilpa Medicare announcements
Oct 2026
29 Oct · Analysts
29 Oct · Board meeting
10 Oct · General Updates
Sep 2026
23 Sep · General Updates
22 Sep · Analysts
Shilpa Medicare share price by year
Each calendar year to 2025.Shilpa Medicare share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 321.15 | −21.2% | 492.90 | 301.83 |
| 2024 | 407.75 | +146.9% | 468.00 | 158.80 |
| 2023 | 165.15 | +18.7% | 191.35 | 114.10 |
| 2022 | 139.18 | −48.0% | 296.73 | 134.08 |
| 2021 | 267.55 | +18.8% | 330.88 | 165.20 |
| 2020 | 225.15 | +59.6% | 332.68 | 121.98 |
| 2019 | 141.05 | −26.8% | 206.73 | 105.00 |
| 2018 | 192.78 | −37.7% | 311.20 | 180.70 |
| 2017 | 309.55 | −10.4% | 364.03 | 275.60 |
| 2016 | 345.45 | +38.7% | 387.88 | 186.70 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 29 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 29 Oct 2026 | 932.00 | 949.80 | 922.90 | 935.60 | 935.87 | 3,86,410 | 43.9% |
| 28 Oct 2026 | 909.00 | 937.30 | 906.00 | 932.00 | 924.27 | 5,73,684 | 52.2% |
| 27 Oct 2026 | 912.60 | 924.00 | 895.10 | 904.70 | 911.54 | 4,08,611 | 36.4% |
| 26 Oct 2026 | 880.00 | 908.90 | 860.00 | 900.80 | 886.05 | 8,71,846 | 38.2% |
| 23 Oct 2026 | 860.80 | 883.00 | 838.80 | 864.30 | 862.24 | 9,55,725 | 41.8% |
| 22 Oct 2026 | 826.30 | 894.20 | 820.40 | 860.80 | 867.49 | 14,94,659 | 29.5% |
| 21 Oct 2026 | 855.10 | 882.90 | 835.80 | 845.20 | 857.14 | 14,15,259 | 47.0% |
| 19 Oct 2026 | 890.00 | 919.90 | 855.20 | 876.20 | 888.17 | 23,30,469 | 48.3% |
| 16 Oct 2026 | 920.00 | 962.00 | 913.00 | 937.60 | 940.99 | 7,22,906 | 42.3% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 3 Oct 2025 | Bonus | 0.5000 | Holders received 1 bonus share for every 1 held. |
| 6 Nov 2015 | Split | 0.5000 | Each share became 2. |
| 16 Jul 2013 | Bonus | 0.6667 | Holders received 1 bonus share for every 2 held. |
| 28 Sep 2007 | Price move | – | Between two trading sessions the price fell 47% or more, or rose 90% or more. No corporate action is on record. Earlier prices are not shown. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it.
Company details
- NSE symbol
- SHILPAMED
- BSE code
- 530549
- ISIN
- INE790G01031
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.vbshilpa.com
- CIN
- L85110KA1987PLC008739
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1987
- Registered office
- 12-6-214/ A1, Hyderabad Road, Raichur 584135, Karnataka
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments